acute coronary syndrome
Conditions
Interventions
Intervention group:Patients in the intervention group were given semaglutide from the first day of enrollment, 0.25 mg subcutaneously in the first week, once a week
If the patient can tolerate it, increase to 0.5mg once a week after 4 weeks
If the patient can tolerate it, increase to 1mg once weekly after 8 weeks.
Control group:The control group received only conventional hypoglycemic therapy (oral hypoglycemic agents and/or insulin).
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age =18 years old; 2. The clinical diagnosis was acute coronary syndrome combined with type 2 diabetes.
Exclusion criteria
Exclusion criteria: 1. Have contraindications for the use of semaglutide, including: allergy to the drug, previous or family history of medullary thyroid tumor, type 2 multiple endocrine tumor syndrome; 2. The patient had not been treated with semaglutide in the past 3 months; Did not receive oral or injectable corticosteroid therapy; 3. In patients with severe renal impairment, the glomerular filtration rate was 5x upper limit; 5. Secondary or primary confusion, cognitive impairment or abnormal mental behavior; 6. Pregnancy or breastfeeding; 7. In addition to the above, the investigator determined that there were other reasons for not being suitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP;Global longitudinal strain; | — |
Secondary
| Measure | Time frame |
|---|---|
| hsCRP;LVEF;Major Adverse Cardiovascular Events; | — |
Countries
China
Contacts
Public ContactXiang Wang
Beijing Hospital
Outcome results
None listed